Brief: Sino Biopharmaceutical Says Application For Phase Ib/Ii Clinical Trial Of Innovative Drug Accepted
16/10/2023 15:51
Oct 16 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK :
* APPLICATION FOR PHASE IB/II CLINICAL TRIAL OF INNOVATIVE
DRUG
"GMA106 (GIPR ANTAGONIST/GLP-1R AGONIST)" ACCEPTED BY CDE
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up